UY39060A - Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 - Google Patents

Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2

Info

Publication number
UY39060A
UY39060A UY0001039060A UY39060A UY39060A UY 39060 A UY39060 A UY 39060A UY 0001039060 A UY0001039060 A UY 0001039060A UY 39060 A UY39060 A UY 39060A UY 39060 A UY39060 A UY 39060A
Authority
UY
Uruguay
Prior art keywords
coronavirus
vaccines
compositions
cov
sars
Prior art date
Application number
UY0001039060A
Other languages
English (en)
Inventor
H Barouch Dan
C Sadoff Jerald
Petrus Maria Langedijk Johannes
Lucy Rutten
Johannes Gerardus BAKKERS Mark
Rinke Bos
Frank Wegmann
Adrianus Theodorus Maria Zuijdgeest David
An Vandebosch
Claude Michel LE GARS Mathieu
Original Assignee
Janssen Pharmaceuticals Inc
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3101131A external-priority patent/CA3101131A1/en
Application filed by Janssen Pharmaceuticals Inc, Beth Israel Deaconess Medical Ct Inc filed Critical Janssen Pharmaceuticals Inc
Publication of UY39060A publication Critical patent/UY39060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Refiere a composiciones inmunogénicas y vacunas conteniendo una proteína de coronavirus o un polinucleótido que codifica una proteína de coronavirus y sus usos. Proporciona métodos para tratar y / o prevenir infección por coronavirus mediante administración de una composición inmunogénica o vacuna al sujeto. Proporciona métodos para detectar y / o monitorear respuesta protectora de anticuerpos anticoronavirus (Ej.: respuesta de anticuerpos neutralizantes anti-coronavirus, anti-2019-nCoV, anti-Spike y / o anti-Spike). Refiere a un ácido nucleico aislado y / o recombinante que codifica una proteína de coronavirus S, a las proteínas de coronavirus S y al uso de las mismas en vacunas.
UY0001039060A 2020-01-31 2021-02-01 Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 UY39060A (es)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US202062969008P 2020-01-31 2020-01-31
US202062994630P 2020-03-25 2020-03-25
US202063014467P 2020-04-23 2020-04-23
US202063025782P 2020-05-15 2020-05-15
US202062705187P 2020-06-15 2020-06-15
US202062705308P 2020-06-21 2020-06-21
US202063043090P 2020-06-23 2020-06-23
US202062706366P 2020-08-12 2020-08-12
US202063066147P 2020-08-14 2020-08-14
US202062706676P 2020-09-02 2020-09-02
US202062706937P 2020-09-18 2020-09-18
US202062706958P 2020-09-21 2020-09-21
US202063198089P 2020-09-28 2020-09-28
US202063198306P 2020-10-09 2020-10-09
US202063112900P 2020-11-12 2020-11-12
CA3101131A CA3101131A1 (en) 2020-01-31 2020-11-28 Compositions and methods for preventing and treating coronavirus infection - sars­cov-2 vaccines
US202063121482P 2020-12-04 2020-12-04
US202163133969P 2021-01-05 2021-01-05
US202163135182P 2021-01-08 2021-01-08
US202163141913P 2021-01-26 2021-01-26
US202163142977P 2021-01-28 2021-01-28

Publications (1)

Publication Number Publication Date
UY39060A true UY39060A (es) 2021-10-29

Family

ID=77079265

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039060A UY39060A (es) 2020-01-31 2021-02-01 Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2

Country Status (9)

Country Link
US (3) US11498944B2 (es)
EP (1) EP4097122A4 (es)
JP (1) JP2023512519A (es)
KR (1) KR20220134622A (es)
CN (1) CN116096732A (es)
BR (1) BR112022014808A2 (es)
TW (1) TW202204380A (es)
UY (1) UY39060A (es)
WO (1) WO2021155323A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260181A1 (en) * 2014-09-16 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
US20240277830A1 (en) 2020-02-04 2024-08-22 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
BR112022015626A2 (pt) 2020-02-07 2022-10-11 Rnaimmune Inc Composição e métodos de vacinas de mrna contra infecção de novo coronavírus
WO2021160346A1 (en) 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
US20210260180A1 (en) * 2020-02-14 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
MX2022010460A (es) 2020-02-25 2022-09-19 Inovio Pharmaceuticals Inc Vacunas contra el coronavirus y metodos de uso.
US11213482B1 (en) * 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
CA3174215A1 (en) 2020-04-22 2021-10-28 Ugur Sahin Coronavirus vaccine
AU2021279312A1 (en) * 2020-05-29 2022-12-15 CureVac SE Nucleic acid based combination vaccines
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022008973A2 (en) * 2020-07-10 2022-01-13 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
US11740240B2 (en) * 2020-07-20 2023-08-29 Bio-Rad Laboratories, Inc. Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
WO2022159433A1 (en) * 2021-01-20 2022-07-28 Singh Biotechnology, Llc Therapeutics directed against coronavirus
JP2022116482A (ja) * 2021-01-29 2022-08-10 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
KR20230160349A (ko) * 2021-03-22 2023-11-23 노바백스, 인코포레이티드 코로나 바이러스 백신 제제
US20220370598A1 (en) * 2021-05-05 2022-11-24 Inovio Pharmaceuticals, Inc. Vaccines Against Coronavirus and Methods of Use
CN113832168B (zh) * 2021-08-15 2023-08-04 北京科兴中维生物技术有限公司 mRNA疫苗及其制备方法和应用
WO2023020939A1 (en) * 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023023940A1 (zh) * 2021-08-24 2023-03-02 复旦大学 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
WO2023026182A1 (en) * 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN116041448A (zh) * 2021-08-26 2023-05-02 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
CN113913464B (zh) * 2021-09-28 2022-11-22 武汉枢密脑科学技术有限公司 一种表达载体、重组腺相关病毒及其在制备2019新型冠状病毒疫苗中的应用
WO2023092100A2 (en) * 2021-11-19 2023-05-25 Meissa Vaccines, Inc. Methods of administering chimeric vaccines
CN116178527A (zh) * 2021-11-26 2023-05-30 深圳先进技术研究院 抗sar-cov-2全人源单克隆抗体6g18及其制法与应用
EP4440613A2 (en) * 2021-11-30 2024-10-09 Novavax, Inc. Coronavirus vaccine formulations
TWI843471B (zh) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
CN114574502B (zh) * 2022-04-11 2023-07-14 四川大学 一种以复制缺陷腺相关病毒为载体的新型冠状病毒疫苗
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
TW202400635A (zh) * 2022-04-20 2024-01-01 美商因諾維奧製藥公司 針對sars-cov-2變異體之免疫原性組合物及其使用方法
WO2023212446A1 (en) * 2022-04-29 2023-11-02 Xequel Bio, Inc. Compositions and methods for treating complications of viral infections and other respiratory disorders
WO2023240278A2 (en) * 2022-06-10 2023-12-14 The Trustees Of Columbia University In The City Of New York Uses of glycolipids as a vaccine adjuvant and methods thereof
WO2023250111A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024008014A1 (zh) * 2022-07-07 2024-01-11 成都威斯克生物医药有限公司 抗SARS-CoV-2或其突变体感染的药物组合物及其联合用药物
WO2024032468A1 (zh) * 2022-08-08 2024-02-15 神州细胞工程有限公司 一种可诱导广谱中和活性重组五组分新冠病毒三聚体蛋白疫苗的制备及应用
WO2024076805A2 (en) * 2022-10-07 2024-04-11 Zeptometrix Llc Control for protein-based assay
WO2024097259A1 (en) * 2022-11-01 2024-05-10 RNAimmune, Inc. Composition and methods for mrna vaccines against novel omicron coronavirus infections
CN116024269B (zh) * 2022-11-18 2024-02-02 复百澳(苏州)生物医药科技有限公司 一种冠状病毒假病毒颗粒的制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
CA2320419C (en) 1998-02-17 2011-02-08 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1232276B8 (en) 1999-11-16 2007-06-27 Genzyme Corporation Vectors and transgenes with regulatory elements for gene delivery to the liver
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
DE60233047D1 (de) 2001-05-14 2009-09-03 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
IL162404A0 (en) 2002-01-18 2005-11-20 Schering Ag Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US7320857B2 (en) * 2003-06-18 2008-01-22 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
US20070270361A1 (en) 2003-08-04 2007-11-22 Shan Lu Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof
US7129042B2 (en) * 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
EP1711518B1 (en) 2004-01-23 2009-11-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Chimpanzee adenovirus vaccine carriers
CA2583843C (en) 2004-10-13 2010-09-21 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
MX2007006524A (es) 2004-12-01 2007-06-22 Genzyme Corp Metodos para el suministro dirigido de material genetico al higado.
AU2006283101B2 (en) 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20090110695A1 (en) 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
SG10201408784SA (en) 2008-11-18 2015-02-27 Beth Israel Hospital Antiviral vaccines with improved cellular immunogenicity
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
BRPI1008018A2 (pt) 2009-02-02 2016-03-15 Okairos Ag ácidos nucleicos de adenovírus símio e sequências de aminoácidos, vetores contendo os mesmos e uso dos mesmos
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
PL2655604T3 (pl) 2010-12-14 2019-02-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
US10960070B2 (en) 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018170347A1 (en) * 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
GB201708444D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Compositions and methods for inducing an immune response
SG11202003398SA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus vectors and uses thereof
EA202091074A1 (ru) 2017-10-31 2020-07-22 Янссен Вэксинс Энд Превеншн Б.В. Аденовирус и его применения
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021154763A1 (en) * 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
WO2021229450A1 (en) * 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Also Published As

Publication number Publication date
US20230075527A1 (en) 2023-03-09
KR20220134622A (ko) 2022-10-05
BR112022014808A2 (pt) 2022-09-20
EP4097122A1 (en) 2022-12-07
JP2023512519A (ja) 2023-03-27
CN116096732A (zh) 2023-05-09
TW202204380A (zh) 2022-02-01
US20210388032A1 (en) 2021-12-16
US11384122B2 (en) 2022-07-12
EP4097122A4 (en) 2024-07-17
US20210246170A1 (en) 2021-08-12
WO2021155323A1 (en) 2021-08-05
US11498944B2 (en) 2022-11-15

Similar Documents

Publication Publication Date Title
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
BR112022014627A2 (pt) Vacina contra coronavírus
MX2023007574A (es) "vacuna de arn contra variantes de sars-cov-2.
BR112022019781A2 (pt) Vacina para o coronavírus
CO2020013588A2 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos
WO2019193183A3 (en) Novel yellow fever nucleic acid molecules for vaccination
MX2018014573A (es) Vacuna contra el virus del zika.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
BR112020016454A8 (pt) Tratamento utilizando rna que codifica citocina
AR124928A2 (es) Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
AR109538A1 (es) Vacuna contra la gripe porcina
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
WO2023094713A3 (en) Coronavirus vaccine
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
BR112022022859A2 (pt) Vacinas contra sars-cov-2
BR112022011885A2 (pt) Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia
BR112022016893A8 (pt) Vacina contra a infecção do vírus da peste suína africana
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus